UroGen Pharma Ltd.
We are a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. We have an innovative and broad pipeline of product candidates that we believe can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Our lead product candidates, MitoGel and VesiGel, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is currently used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.
|Address||9 Ha’Ta’asiya Street, Ra’anana 4365007, Israel|
|Phone Number||+972 (9) 770-7601|
|View Prospectus:||UroGen Pharma Ltd.|
|Revenues||$17.5 mil (last 12 months)|
|Net Income||$-1.9 mil (last 12 months)|
|Price range||$12.00 - $14.00|
|Est. $ Volume||$45.0 mil|
|Manager / Joint Managers||Jefferies/ Cowen and Company|
|CO-Managers||Raymond James/ Oppenheimer|
|Expected To Trade:||5/4/2017|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|